CEL-SCI (NYSE:CVM – Get Free Report) and Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.
Volatility & Risk
CEL-SCI has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 2.63, meaning that its share price is 163% more volatile than the S&P 500.
Earnings & Valuation
This table compares CEL-SCI and Tectonic Therapeutic”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CEL-SCI | N/A | N/A | -$26.92 million | ($0.51) | -0.77 |
| Tectonic Therapeutic | N/A | N/A | $12.16 million | ($5.89) | -7.16 |
Analyst Ratings
This is a breakdown of recent ratings and price targets for CEL-SCI and Tectonic Therapeutic, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CEL-SCI | 0 | 0 | 0 | 0 | 0.00 |
| Tectonic Therapeutic | 0 | 0 | 5 | 1 | 3.17 |
Tectonic Therapeutic has a consensus price target of $72.25, indicating a potential upside of 71.21%. Given Tectonic Therapeutic’s stronger consensus rating and higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than CEL-SCI.
Profitability
This table compares CEL-SCI and Tectonic Therapeutic’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CEL-SCI | N/A | -228.43% | -100.46% |
| Tectonic Therapeutic | N/A | -35.53% | -31.97% |
Insider & Institutional Ownership
12.1% of CEL-SCI shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 16.2% of CEL-SCI shares are held by insiders. Comparatively, 9.2% of Tectonic Therapeutic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Tectonic Therapeutic beats CEL-SCI on 9 of the 12 factors compared between the two stocks.
About CEL-SCI
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
About Tectonic Therapeutic
Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.
